The strong correlation between NAFLD and metabolic disorders, such as obesity and T2DM, suggests that targeting the GLP-1 may be a promising therapeutic strategy for NAFLD. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.